Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on 2seventy Bio to $25 from $28 and keeps an Overweight rating on the shares. The firm has updated its BCMA CAR-T market model and modestly lowered uptake for Abecma in the third-line and later setting in the outer years of its projection period to account for competitive pressure from Carvykti, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSVT: